ENGINEERED LUCIFERASES

• US 20090286299A1
• Filed: 05/15/2009
• Published: 11/19/2009
• Est. Priority Date: 05/15/2008
• Status: Abandoned Application

• Current Assignee: Illumina Incorporated
• Original Assignee: Illumina Incorporated
• Inventors: Bazargan, Leila, Ronaghi, Mostafa, Eltoukhy, Helmy A.
• Application Number:
  US12/467,222
• Publication Number:
  US 20090286299A1
• Time in Patent Office: Days
• US Class Current: 435/174
• CPC Class Codes: C12N 9/0069 acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
• CPC Class Codes: C12Q 1/66 involving luciferase

Abstract

DNA sequencing techniques are important for a variety of research and diagnostic applications. Pyrosequencing is a “sequencing by synthesis” technique that makes use of luciferase. Modified luciferase enzymes and methods of DNA pyrosequencing are provided. Means of preparing and producing mutant luciferases that have enhanced selectivity for ATP or dATP are described.

Claims

1. A modified luciferase comprising a selectivity for ATP over dATP that is at least three-fold greater than the selectivity for ATP over dATP of an unmodified luciferase from the same organism.

2. The modified luciferase of claim 1, wherein the selectivity for ATP over dATP is at least eight-fold greater then the selectivity for ATP over dATP of an unmodified luciferase from the same organism.

3. The modified luciferase of claim 1, further comprising a light emitting activity that is greater than the light emitting activity of said unmodified luciferase.

4. The modified luciferase of claim 1 having an altered amino acid sequence as compared to the amino acid sequence of an unmodified luciferase from the same organism.

5. The modified luciferase of claim 4, wherein said modified luciferase is from Photinus pyralis.

6. The modified luciferase of claim 5, wherein the altered amino acid sequence comprises an amino acid substitution.

7. The modified luciferase of claim 6, wherein the amino acid substitution is located in the primary amino acid sequence between the N-terminus and the first amino acid forming the active site of said modified luciferase.

8. The modified luciferase of claim 6, wherein the amino acid substitution comprises a conservative amino acid substitution.

9. The modified luciferase of claim 6, wherein the amino acid substitution is selected from the group consisting of N197, S198, H244, I423 and any combination thereof.

10. The modified luciferase of claim 9, wherein the amino acid substitution is selected from the group consisting of N197F, S198T, H244F, I423Y and any combination thereof.

11. The modified luciferase of claim 1, further comprising greater thermostability than said unmodified luciferase.

12. The modified luciferase of claim 6, further comprising greater thermostability than said unmodified luciferase.

13. The modified luciferase of claim 12, wherein the amino acid substitution is selected from the group consisting of T214, I232, F295, E354, and any combination thereof.

14. The modified luciferase of claim 13, wherein the amino acid substitution is selected from the group consisting of T214A, I232A, F295L, E354K, and any combination thereof.

15. The modified luciferase of claim 1 further comprising a biotin binding moiety.

16. The modified luciferase of claim 6, further comprising a biotin binding moiety.

17. The modified luciferase of claim 16, wherein the biotin binding moiety comprises a polypeptide.

18. The modified luciferase of claim 17, wherein the polypeptide has at least 70% identity to SEQ ID NO:

1.

19. The modified luciferase of claim 18, wherein the amino acid substitution is selected from the group consisting of T214A, I232A, F295L, E354K, N197F, S198T, H244F, I423Y and any combination thereof.

20. The modified luciferase of claim 6, wherein the altered amino acid sequence comprises an amino acid substitution within 10 Angstroms of a binding site for a nucleotide or a binding site for luciferin in the tertiary structure of the modified luciferase.

21. The modified luciferase of claim 20, wherein the amino acid substitution is within 5 Angstroms of the binding site for a nucleotide or the binding site for luciferin.

22. The modified luciferase of claim 1, associated with a solid support.

23. The modified luciferase of claim 21, wherein the solid support comprises a particle.